This Article Full Text Full Text (PDF) CME: Take the course for this article: Circulation: August 14, 2007, Volume 116, Number 7 All Versions of this Article: 116/7/745    most recent CIRCULATIONAHA.106.686048v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Airoldi, F. Articles by Grube, E. Search for Related Content PubMed PubMed Citation Articles by Airoldi, F. Articles by Grube, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID TAXOL Medline Plus Health Information Blood Thinners Related Collections Catheter-based coronary interventions: stents

(Circulation. 2007;116:745-754.)
© 2007 American Heart Association, Inc.

Interventional Cardiology

Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment

Flavio Airoldi, MD^*; Antonio Colombo, MD^*; Nuccia Morici, MD; Azeem Latib, MD; John Cosgrave, MD; Lutz Buellesfeld, MD; Erminio Bonizzoni, MD; Mauro Carlino, MD; Ulrich Gerckens, MD; Cosmo Godino, MD; Gloria Melzi, MD; Iassen Michev, MD; Matteo Montorfano, MD; Giuseppe Massimo Sangiorgi, MD; Asif Qasim, MD; Alaide Chieffo, MD; Carlo Briguori, MD, PhD; Eberhard Grube, MD

From Invasive Cardiology Unit (F.A., A. Colombo, N.M., A.L., M.C., C.G., G.M., I.M., M.M., G.M.S., A. Chieffo), San Raffaele Scientific Institute, Milan, Italy; Emo Centro Cuore Columbus (A. Colombo, J.C., G.M.S., A.Q.), Milan, Italy; Department of Cardiology and Angiology, Helios Heart Center Siegburg (L.B., U.G., E.G.), Siegburg, Germany; Institute of Medical Statistics and Biometry (E.B.), University of Milan, Milan, Italy; and Laboratory of Interventional Cardiology Clinica Mediterranea (C.B.), Naples, Italy.

Correspondence to Antonio Colombo, MD, EMO Centro Cuore Columbus Hospital, Via Buonarroti, 48-20145, Milan, Italy. E-mail info{at}emocolumbus.it

Received December 21, 2006; accepted May 25, 2007.

Background— The need for prolonged aspirin and thienopyridine therapy and the risk of stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents.

Methods and Results— A prospective observational cohort study was conducted between June 2002 and January 2004 on 3021 patients consecutively and successfully treated in 5389 lesions with drug-eluting stents. Detailed patient information was collected on antiplatelet therapy. We analyzed the incidence of ST throughout the 18-month follow-up period and its relationship with thienopyridine therapy. ST occurred in 58 patients (1.9%) at 18 months. Forty-two patients (1.4%) experienced the event within 6 months of stent implantation. Acute myocardial infarction (fatal or nonfatal) occurred in 46 patients (79%) and death in 23 patients (39%) with ST. The median interval from discontinuation of thienopyridine therapy to ST was 13.5 days (interquartile range 5.2 to 25.7 days) for the first 6 months and 90 days (interquartile range 30 to 365 days) between 6 and 18 months. On multivariable analysis, the strongest predictor for ST within 6 months of stenting was discontinuation of thienopyridine therapy (hazard ratio, 13.74; 95% CI, 4.04 to 46.68; P<0.001). Thienopyridine discontinuation after 6 months did not predict the occurrence of ST (hazard ratio, 0.94; 95% CI, 0.30 to 2.98; P=0.92).

Conclusions— Discontinuation of thienopyridine therapy was the major determinant of ST within the first 6 months, but insufficient information is available to determine whether there is benefit in continuing a thienopyridine beyond 6 months.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur. Heart J., November 2, 2009; 30(22): 2714 - 2721. [Abstract] [Full Text] [PDF]

				D. E. Kandzari, A. Colombo, S.-J. Park, C. L. Tommaso, S. G. Ellis, L. A. Guzman, P. S. Teirstein, C. Tamburino, J. Ormiston, G. W. Stone, et al. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1576 - 1588. [Abstract] [Full Text] [PDF]

				B. Lagerqvist, J. Carlsson, O. Frobert, J. Lindback, F. Schersten, U. Stenestrand, S. K. James, and for the Swedish Coronary Angiography and Angioplas Stent Thrombosis in Sweden: A Report From the Swedish Coronary Angiography and Angioplasty Registry Circ Cardiovasc Interv, October 1, 2009; 2(5): 401 - 408. [Abstract] [Full Text] [PDF]

				A. S.P. Sharp, A. Latib, A. Ielasi, C. Larosa, C. Godino, M. Saolini, V. Magni, R. T. Gerber, M. Montorfano, M. Carlino, et al. Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures Circ Cardiovasc Interv, October 1, 2009; 2(5): 416 - 422. [Abstract] [Full Text] [PDF]

				K J Harjai, C Shenoy, P Orshaw, and J Boura Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry Heart, October 1, 2009; 95(19): 1579 - 1586. [Abstract] [Full Text] [PDF]

				A. Perez de Prado, C. Cuellas, A. Diego, A. de Miguel, and F. Fernandez-Vazquez Platelet reactivity and stent thrombosis: still some issues to solve. J. Am. Coll. Cardiol., August 11, 2009; 54(7): 666 - 667. [Full Text] [PDF]

				A. Schomig, N. Sarafoff, and M. Seyfarth Triple antithrombotic management after stent implantation: when and how? Heart, August 1, 2009; 95(15): 1280 - 1285. [Full Text] [PDF]

				J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al. Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries Circ Cardiovasc Interv, August 1, 2009; 2(4): 285 - 293. [Abstract] [Full Text] [PDF]

				J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 583 - 593. [Abstract] [Full Text] [PDF]

				H. Otake, J. Shite, J. Ako, T. Shinke, Y. Tanino, D. Ogasawara, T. Sawada, N. Miyoshi, H. Kato, B.-K. Koo, et al. Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 459 - 466. [Abstract] [Full Text] [PDF]

				J. W. van Werkum, A. A. Heestermans, A. C. Zomer, J. C. Kelder, M.-J. Suttorp, B. J. Rensing, J. J. Koolen, B.R. G. Brueren, J.-H. E. Dambrink, R. W. Hautvast, et al. Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry J. Am. Coll. Cardiol., April 21, 2009; 53(16): 1399 - 1409. [Abstract] [Full Text] [PDF]

				P. Massoudy, M. Thielmann, N. Lehmann, A. Marr, G. Kleikamp, A. Maleszka, A. Zittermann, R. Korfer, M. Radu, A. Krian, et al. Impact of prior percutaneous coronary intervention on the outcome of coronary artery bypass surgery: A multicenter analysis J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 840 - 845. [Abstract] [Full Text] [PDF]

				D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati, and N. von Beckerath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 849 - 856. [Abstract] [Full Text] [PDF]

				T. Kimura, T. Morimoto, Y. Nakagawa, T. Tamura, K. Kadota, H. Yasumoto, H. Nishikawa, Y. Hiasa, T. Muramatsu, T. Meguro, et al. Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation Circulation, February 24, 2009; 119(7): 987 - 995. [Abstract] [Full Text] [PDF]

				J. W. van Werkum, A. A.C.M. Heestermans, F. I. de Korte, J. C. Kelder, M.-J. Suttorp, B. J.W.M. Rensing, B. Zwart, B. R. G. Brueren, J. J. Koolen, J.-H. E. Dambrink, et al. Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis: An Analysis of 431 Cases Circulation, February 17, 2009; 119(6): 828 - 834. [Abstract] [Full Text] [PDF]

				G. W. Stone, M. Midei, W. Newman, M. Sanz, J. B. Hermiller, J. Williams, N. Farhat, R. Caputo, N. Xenopoulos, R. Applegate, et al. Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial Circulation, February 10, 2009; 119(5): 680 - 686. [Abstract] [Full Text] [PDF]

				J. Aoki, A. J. Lansky, R. Mehran, J. Moses, M. E. Bertrand, B. T. McLaurin, D. A. Cox, A. M. Lincoff, E. M. Ohman, H. D. White, et al. Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial Circulation, February 10, 2009; 119(5): 687 - 698. [Abstract] [Full Text] [PDF]

				S.-J. Park and D.-W. Park Percutaneous Coronary Intervention With Stent Implantation Versus Coronary Artery Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Is It Time to Change Guidelines? Circ Cardiovasc Interv, February 1, 2009; 2(1): 59 - 68. [Abstract] [Full Text] [PDF]

				C. Terpening An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events J Am Board Fam Med, January 1, 2009; 22(1): 51 - 56. [Abstract] [Full Text] [PDF]

				M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET Eur. Heart J., January 1, 2009; 30(1): 16 - 24. [Abstract] [Full Text] [PDF]

				F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021. [Abstract] [Full Text] [PDF]

				A. K. Chhatriwalla and D. L. Bhatt Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 217 - 225. [Full Text] [PDF]

				A. Colombo and R. T. Gerber Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 226 - 232. [Full Text] [PDF]

				R. Sanz-Ruiz and F. Fernandez-Aviles European perspective on the use of antiplatelet agents in atherothrombotic disease Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I14 - I18. [Abstract] [Full Text] [PDF]

				R. A. Byrne and A. Kastrati Duration of antiplatelet therapy following intracoronary stenting: are changes needed? Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I25 - I29. [Abstract] [Full Text] [PDF]

				D.-W. Park, S.-C. Yun, S.-W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, S.-S. Cheong, J.-J. Kim, S.-W. Park, and S.-J. Park Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 494 - 503. [Abstract] [Full Text] [PDF]

				P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al. Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1134 - 1140. [Abstract] [Full Text] [PDF]

				M. E. Pfisterer Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised Circulation, September 9, 2008; 118(11): 1117 - 1119. [Full Text] [PDF]

				A. Chieffo, S.-J. Park, E. Meliga, I. Sheiban, M. S. Lee, A. Latib, Y.-H. Kim, M. Valgimigli, D. Sillano, V. Magni, et al. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry Eur. Heart J., September 1, 2008; 29(17): 2108 - 2115. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF]

				S.-H. Choi, A. Prasad, and S. Tsimikas The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2228 - 2229. [Full Text] [PDF]

				S. Francescone and J. L. Halperin "Triple Therapy" or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents J. Am. Coll. Cardiol., February 26, 2008; 51(8): 826 - 827. [Full Text] [PDF]

				F. Saia, A. Marzocchi, and A. Branzi Review: The safety of drug-eluting stents Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52. [Abstract] [PDF]

				A. A. Bavry and D. L. Bhatt Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor? Circulation, August 14, 2007; 116(7): 696 - 699. [Full Text] [PDF]